Company Analysis Аптеки 36 и 6
1. Summary
Advantages
- Price (11.59 ₽) is less than fair price (15.77 ₽)
- Current debt level 0% is below 100% and has decreased over 5 years from 114.97%.
Disadvantages
- Dividends (0%) are below the sector average (10.19%).
- The stock's return over the last year (-22.55%) is lower than the sector average (-5.66%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=6.38%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Аптеки 36 и 6 | Ритейл | Index | |
|---|---|---|---|
| 7 days | -3.9% | 2% | 1.2% |
| 90 days | 10.6% | 14.1% | 11.8% |
| 1 year | -22.6% | -5.7% | -10.1% |
APTK vs Sector: Аптеки 36 и 6 has significantly underperformed the "Ритейл" sector by -16.89% over the past year.
APTK vs Market: Аптеки 36 и 6 has significantly underperformed the market by -12.41% over the past year.
Stable price: APTK is not significantly more volatile than the rest of the market on "Московская биржа" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APTK with weekly volatility of -0.4337% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (11.59 ₽) is lower than the fair price (15.77 ₽).
Price significantly below the fair price: The current price (11.59 ₽) is 36.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (6.71).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (14.68).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is higher than that of the sector as a whole (-17.95).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (10.15).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (0.6848).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (1.91).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (22.42).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (2.22).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-20%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (6.38%).
ROE vs Market: The company's ROE (0%) is lower than that of the market as a whole (68.42%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (9.12%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (17.61%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (11.7%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.32%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '10.19%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
9. Stocks forum Аптеки 36 и 6
9.1. Stocks forum - Latest comments
9.2. Latest Blogs
Утренний обзор: чего ждать от рынка?
В понедельник индекс Мосбиржи закрылся в нуле.
2800 удержан, но может быть повторный штурм!
Нефть выросла на 1,5% за 2 дня на угрозах Байдена о запрете бурения скважин и все еще не особо закрепилась выше уровня 77,21 - на перекупленности можем увидеть какой-либо откат....
More
💊 Слыхали про супер-лекарство от наших фарм-компаний?
- ❌ Нет ?
Да я тоже нет, но судя по темпам роста , - оно есть.
🦠 Что там за напасть в Китае (где ж ещё опять) ?
Метапневмовирус - является одним из возбудителей респираторных инфекций, был открыт аж в в 2001 году.
Чаще всего вызывает острые респираторные инфекции, включая бронхиолит, пневмонию....
More
All blogs ⇨
